BLCM:NSD-Bellicum Pharmaceuticals, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 3.18

Change

+0.07 (+2.25)%

Market Cap

USD 0.03B

Volume

0.15M

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Bellicum Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen; and BPX-603, a dual-switch GoCAR-T product candidate that is in Phase 1/2 clinical trials to treat solid tumors that express the human epidermal growth factor receptor 2 antigens. Its clinical product candidates also include Rivo-cel, an allogeneic T cell product candidate intended to enhance outcomes when administered after hematopoietic stem cell transplantation in the treatment of hematologic malignancies and inherited blood disorders. It has collaboration and license agreements with Adaptimmune Therapeutics plc; Agensys, Inc.; BioVec Pharma, Inc.; ARIAD Pharmaceuticals, Inc.; and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was incorporated in 2004 and is based in Houston, Texas.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-06-17 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

+4.63 (+2.34%)

USD79.44B 132.60 106.34
REGN Regeneron Pharmaceuticals, Inc

+12.43 (+2.37%)

USD55.78B 14.90 11.77
BNTX BioNTech SE

+10.35 (+5.08%)

USD49.23B -99,999.99 35.63
VRTX Vertex Pharmaceuticals Incorpo..

+0.87 (+0.46%)

USD48.53B 17.87 12.86
ALXN Alexion Pharmaceuticals, Inc

-0.58 (-0.32%)

USD39.90B 58.60 42.42
BGNE BeiGene, Ltd

-4.17 (-1.25%)

USD31.22B N/A N/A
GMAB Genmab A/S

-1.04 (-2.33%)

USD29.17B 26.59 3.71
SGEN Seagen Inc

+2.06 (+1.36%)

USD27.46B 42.22 39.29
RPRX Royalty Pharma plc

+0.52 (+1.19%)

USD26.73B 22.60 15.75
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing BLCM

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -9.92% 39% F 19% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -9.92% 39% F 19% F
Trailing 12 Months  
Capital Gain -64.55% 5% F 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -64.55% 5% F 2% F
Trailing 5 Years  
Capital Gain -73.89% 23% F 6% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -73.89% 23% F 6% F
Average Annual (5 Year Horizon)  
Capital Gain 33.44% 65% D 79% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 33.44% 65% D 78% C+
Risk Return Profile  
Volatility (Standard Deviation) 173.32% 13% F 8% F
Risk Adjusted Return 19.29% 46% F 38% F
Market Capitalization 0.03B 2% F 4% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 40.34 4% F 3% F
Price / Cash Flow Ratio -0.46 11% F 58% F
EV/EBITDA 0.07 83% B 97% A+
Management Effectiveness  
Return on Equity -378.68% 4% F 2% F
Return on Invested Capital 0.06% 87% B+ 51% F
Return on Assets -46.44% 15% F 5% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 6.26 42% F 24% F
Short Percent 14.53% 14% F 11% F
Beta 1.74 30% F 20% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Underpriced on free cash flow basis

The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector